Drugs / Atebimetinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07562152 | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Immuneering Corporation | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atebimetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07562152 ↗ |
| Route | Oral | “Once daily oral tablets” NCT07562152 ↗ |